Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NTTG who wrote (12201)	7/9/2013 3:29:49 PM
From: Howard Williams	2 Recommendations Recommended By boomertree2 mplaut Read Replies (1) of 13111

NTTG, your opinions regarding virtually all aspects of PVCT are abundantly clear. I'm not here to debate those with you. I am, however, interested in hearing what you feel about efforts at the Moffitt Cancer Center in Tampa, FL where a number of investigators have been and continue to be involved in PV-10 studies. References have been made to a search for the "Holy Grail" of cancer therapies. The February 2013 issue of "Cancer Watch" (article on pages 21 to 23) had several comments by Moffitt scientists indicating they have a high interest in PV-10 cancer therapies. They are currently running a clinical study using fifteen human subjects to assess PV-10's MOA and immune enhancement effects. From the article: "This is a straightforward study that will give a yes or no answer," Dr. Sarniak said. If the Moffitt work, done independently from PVCT (other than PVCT providing the PV-10), provides a clear understanding of PV-10's MOA and indications that PV-10 can play an important role in combination therapies, will that alter your feelings about PV-10's utility and prospects?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next